PURPOSE: Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) plays a role in cellular proliferation, migration, and apoptosis. The current study aimed to analyze whether soluble TWEAK levels are associated with the severity of coronary arterial disease (CAD) in CKD patients. METHODS: Ninety-seven patients diagnosed with CKD stages 2-3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. RESULTS: Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r (2) = 0.287). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01). CONCLUSIONS: Our results indicate a relationship between sTWEAK levels and CAD in CKD stages 2-3 patients.
PURPOSE:Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) plays a role in cellular proliferation, migration, and apoptosis. The current study aimed to analyze whether soluble TWEAK levels are associated with the severity of coronary arterial disease (CAD) in CKDpatients. METHODS: Ninety-seven patients diagnosed with CKD stages 2-3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. RESULTS: Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r (2) = 0.287). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01). CONCLUSIONS: Our results indicate a relationship between sTWEAK levels and CAD in CKD stages 2-3 patients.
Authors: Luis M Blanco-Colio; Jose L Martín-Ventura; Begoña Muñóz-García; Josune Orbe; Jose A Páramo; Jean-Baptiste Michel; Alberto Ortiz; Olivier Meilhac; Jesús Egido Journal: Arterioscler Thromb Vasc Biol Date: 2007-02-01 Impact factor: 8.311
Authors: Ronald M A Henry; Piet J Kostense; Griët Bos; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Lex M Bouter; Coen D A Stehouwer Journal: Kidney Int Date: 2002-10 Impact factor: 10.612
Authors: Begoña Muñoz-García; Juan Antonio Moreno; Oscar López-Franco; Ana Belén Sanz; José Luis Martín-Ventura; Julia Blanco; Aniela Jakubowski; Linda C Burkly; Alberto Ortiz; Jesús Egido; Luis Miguel Blanco-Colio Journal: Arterioscler Thromb Vasc Biol Date: 2009-09-24 Impact factor: 8.311
Authors: Ana B Sanz; Maria Dolores Sanchez-Niño; Maria Concepcion Izquierdo; Aniela Jakubowski; Pilar Justo; Luis M Blanco-Colio; Marta Ruiz-Ortega; Jesús Egido; Alberto Ortiz Journal: J Cell Mol Med Date: 2009-05-01 Impact factor: 5.310
Authors: Mehmet Kanbay; Aslihan Yerlikaya; Alan A Sag; Alberto Ortiz; Masanari Kuwabara; Adrian Covic; Andrzej Wiecek; Peter Stenvinkel; Baris Afsar Journal: Clin Kidney J Date: 2019-09-18